Collaborative Care for Heart Failure Patients With the Metabolic Syndrome
NCT ID: NCT00293852
Last Updated: 2020-03-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
114 participants
INTERVENTIONAL
2006-02-28
2015-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. fewer admissions to hospitals for illness
2. better blood pressure, sugar, fat and heart failure control
3. better patient satisfaction and knowledge about their diseases
4. lower levels of inflammation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiometabolic evalUation REgistry of Heart Failure
NCT06939985
Improving Care of Patients With Heart Failure
NCT01461681
Identifying Targets of Maladaptive Metabolic Responses in Heart Failure
NCT03032627
Monocyte Phenotypic Changes in Heart Failure
NCT02997462
Hospital-Community-Family-Care Management Platform for Chronic Heart Failure
NCT02029287
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis:
Compared to usual post-discharge follow-up, collaborative treatment of heart failure patients with the metabolic syndrome by a team composed of an endocrinologist, cardiologist, patient educator, nurse and case manager will result in:
* Decreased hospital readmissions and emergency room visits
* Health care cost savings
* Increased achievement of treatment goals (target blood pressure, HgbA1c, lipids, and heart failure medication titration)
* Improved patient satisfaction, knowledge, and compliance
* Lower levels of markers of inflammation and insulin resistance
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Usual Care
No interventions assigned to this group
Collaborative Care
Outpatient clinic follow-up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Outpatient clinic follow-up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥18 years
* Admitted to the hospital with a primary diagnosis of heart failure (need not be their first admission for heart failure)
* Meets the modified Framingham criteria for the diagnosis of heart failure (2 major OR 1 major / 2 minor are required):
MAJOR: paroxysmal nocturnal dyspnea (sudden shortness of breath at night), orthopnea (shortness of breath when supine), elevated jugular venous pressure, rales, the presence of an S3 heart sound, cardiomegaly on chest X-ray, pulmonary edema on chest X-ray
MINOR: lower extremity edema, night cough, dyspnea on exertion, hepatomegaly, pleural effusion on chest X-ray, heart rate \> 120 bpm, weight loss \> 10 pounds in 5 days while in hospital
• Meets the National Cholesterol Education Panel criteria for the metabolic syndrome (3 of 5 criteria must be present):
* waist \> 40 in for men, 35 in for women
* blood pressure ≥ 130/85 mmHg or hypertension
* triglycerides ≥150 mg/dL
* fasting glucose ≥ 100 mg/dL or diabetes
* high density lipoprotein level (HDL) \< 40 mg/dL for men, \<50 for women
Exclusion Criteria
* Factors that may limit adherence to interventions or affect conduct of the trial
* Unable or unwilling to given informed consent
* Mental incapacity that limits patient's ability to live independently and benefit from patient education
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Baylor College of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Allison Pritchett
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Allison M. Pritchett, M.D.
Role: PRINCIPAL_INVESTIGATOR
Baylor College of Medicine
Ramaswami Nalini, M.B.B.S
Role: PRINCIPAL_INVESTIGATOR
Baylor College of Medicine
Ashok Balasubramanyam, M.D.
Role: PRINCIPAL_INVESTIGATOR
Baylor College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ben Taub General Hospital
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-18155
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.